Skip to content
Advertisement
Zoetis wins USDA license for 3-in-1 chicken vaccine

Zoetis wins USDA license for 3-in-1 chicken vaccine

Poulvac Procerta HVT-ND-ILT targets Marek’s disease, Newcastle disease and infectious laryngotracheitis.

Key takeaways

  • The USDA has licensed Zoetis’ Poulvac® Procerta® HVT-ND-ILT, a vector vaccine for chickens.
  • Zoetis designed the vaccine to protect against Marek’s disease, Newcastle disease and infectious laryngotracheitis.
  • The label covers healthy one-day-old chickens or 18- to 19-day-old embryonated chicken eggs.

In a Zoetis regulatory action announced on 2026-11-19, Zoetis said the US Department of Agriculture (USDA) has licensed Poulvac® Procerta® HVT-ND-ILT, a vector vaccine for chickens. The vaccine brings three disease targets together in one product.

According to the release, Zoetis designed the vaccine to protect chickens against Marek’s disease (MD), Newcastle disease (ND) and infectious laryngotracheitis (ILT). The company called the license an important milestone in its continued investment and industry leadership in poultry health.

Zoetis regulatory action: the details

Agency US Department of Agriculture (USDA)
Action License for Poulvac® Procerta® HVT-ND-ILT vector vaccine for chickens
  • “The USDA license is an important achievement for our poultry business and reflects Zoetis’ commitment to advancing practical solutions for customers,” said Abhay Nayak, Executive Vice President and President, U.S. Commercial Operations at Zoetis.
  • ILT remains an economically significant respiratory disease, with outbreaks capable of causing significant losses in flocks.

Zoetis said it designed the vaccine to provide early, long-lasting protection against the three diseases. The label covers administration to healthy one-day-old chickens or 18- to 19-day-old embryonated chicken eggs. Producers can include it in seasonal or rotational ILT programs that also use modified-live vaccines.

The company said the product complements other Poulvac® hatchery and immune-complex vaccines. Those address infectious bursal disease, infectious bronchitis, Salmonella and E. coli. Zoetis poultry specialists also help customers plan and implement targeted vaccination programs.

Advertisement

According to Zoetis, tailored support can include technical guidance, diagnostic testing and analysis, hatchery services and team training. The company also offers vaccine audits and flock-health assessments.

Background to the Zoetis regulatory action

Zoetis describes itself as the world’s leading animal health company, with a legacy of nearly 75 years. It supports veterinarians, livestock producers and pet owners in over 100 countries. The company works across medicines, vaccines, diagnostics, biopharmaceuticals and digital solutions. Zoetis Inc. trades on the NYSE under the ticker ZTS and lists Parsippany as its dateline.

What this means

For holders of ZTS, Zoetis said the license adds a new option to its poultry vaccine portfolio for veterinarians and poultry producers building flock-health programs. How customers fold the vaccine into their programs remains open.

Analysis

The USDA license gives Zoetis a 3-in-1 vector vaccine to offer alongside its existing Poulvac® hatchery and immune-complex products. Combining three disease targets in one vaccine may strengthen the company’s standing with poultry veterinarians and producers, given that Zoetis calls ILT an economically significant respiratory disease capable of causing significant losses in flocks.

For ZTS holders, the significance likely rests on adoption by customers. The pace at which veterinarians fold the vaccine into seasonal or rotational ILT programs, and how it sits beside modified-live vaccines, remains an open question for the poultry business.

What to watch

  • Commercial rollout of Poulvac Procerta HVT-ND-ILT. Customer uptake will show whether the license adds meaningfully to Zoetis’ poultry business.
  • Next Zoetis quarterly report. Results will show how the poultry vaccine portfolio performs after the license.

The crypto angle

More market coverage: Crypto Briefing Markets

Source: Zoetis, 2026-11-19 12:30 UTC

Disclosure: This article was edited by Vivian Nguyen. For more information on how we create and review content, see our Editorial Policy.